Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,026.00GBp
12:12pm EDT
Change (% chg)

-96.00p (-1.87%)
Prev Close
5,122.00p
Open
5,118.00p
Day's High
5,128.00p
Day's Low
5,007.00p
Volume
2,701,357
Avg. Vol
2,754,233
52-wk High
5,505.00p
52-wk Low
3,680.00p

Select another date:

BRIEF-FDA approves Astrazeneca's blood-based companion diagnostic for Tagrisso (osimertinib)

* U.S. FDA has approved a blood-based companion diagnostic for Tagrisso (osimertinib) Source text for Eikon: Further company coverage:

AstraZeneca pulls cancer drug application in Europe

LONDON AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised by regulators reviewing the product.

BRIEF-Astrazeneca says to withdraw EU marketing application for cancer drug

* To withdraw marketing authorisation application submitted to European Medicines Agency's Committee for Medicinal Products for Human Use in June 2015 for Cediranib

AstraZeneca pulls cancer drug application in Europe

LONDON, Sept 21 AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised by regulators reviewing the product.

BRIEF-AstraZeneca announces phase 3 combination trial of BYDUREON and FARXIGA

* Phase 3 combination trial of BYDUREON and FARXIGA shows significant blood sugar reduction in patients with type 2 diabetes

Aspen Pharmacare moves into China as South Africa sales dip

JOHANNESBURG South Africa's Aspen Pharmacare Holdings will use its recent acquisitions of GlaxoSmithKline and AstraZeneca product lines to move into China, the firm's chief executive said.

BRIEF-Avara acquires Astrazeneca UK manufacturing facility

* Avara Pharmaceutical Services -About 210 Avlon employees will remain employed; plant will continue to manufacture Astrazeneca products on contract Source text for Eikon: Further company coverage:

AstraZeneca seeks edge over rivals in severe asthma treatment

LONDON AstraZeneca hopes to convince doctors its experimental injection for severe asthma has an edge over two approved rivals after clinical trials data on Monday showed it worked well when given just once every two months.

BRIEF-Astrazeneca completes Aspen agreement

* Completes commercialisation agreement with Aspen for anaesthetics portfolio

BRIEF-Aspen Pharmacare to buy exclusive rights to commercialise AstraZeneca's anaesthetics portfolio

* Had signed an agreement with AstraZeneca whereby AGI will acquire exclusive rights to commercialise astrazeneca's global (excluding USA) anaesthetics portfolio

Select another date: